Neoadjuvant Chemoradiotherapy Combined With CTLA-4 Monoclonal Antibody Plus PD-1 Monoclonal Antibody for Locally Advanced Esophageal Cancer

NCT07751055 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

51

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma (ESCC)

Interventions

DRUG: Ipilimumab (1mg/kg)
DRUG: Sinitilimab
DRUG: Nab-paclitaxel + Cisplatin
RADIATION: IMRT combine with cisplatin concurrent chemotherapy

Sponsor

Sun Yat-sen University